2021
Corticosteroid use in chronic dermatologic disorders and osteoporosis
Lupsa BC, Insogna KL, Micheletti RG, Caplan A. Corticosteroid use in chronic dermatologic disorders and osteoporosis. International Journal Of Women's Dermatology 2021, 7: 545-551. PMID: 35024411, PMCID: PMC8721058, DOI: 10.1016/j.ijwd.2021.07.014.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsGlucocorticoid-induced osteoporosisGlucocorticoid therapyChronic dermatologic disordersUse of glucocorticoidsSerious side effectsGlucocorticoid useCorticosteroid useBone healthBone lossDermatologic disordersSide effectsPatientsOsteoporosisGlucocorticoidsTherapyCase vignettesRiskComplicationsDermatologists
2019
Personalized Management of Type 2 Diabetes
Peter PR, Lupsa BC. Personalized Management of Type 2 Diabetes. Current Diabetes Reports 2019, 19: 115. PMID: 31686226, DOI: 10.1007/s11892-019-1244-0.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetesManagement of patientsUnique patient characteristicsSpecific patient subpopulationsClass of agentsGlycemic targetsTreatment landscapeMedical therapyPatient characteristicsPharmacotherapeutic optionsPatient subpopulationsIndividualized carePersonalized managementClinical practiceType 2ReviewOur goalRecent FindingsWePatientsDiabetesTherapyManagementPhysiciansCare
2009
Efficacy of leptin therapy in the different forms of human lipodystrophy
Chong AY, Lupsa BC, Cochran EK, Gorden P. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia 2009, 53: 27. PMID: 19727665, DOI: 10.1007/s00125-009-1502-9.Peer-Reviewed Original ResearchConceptsForms of lipodystrophyLipodystrophy patientsLeptin therapyLeptin replacementSerum triacylglycerolOpen-label prospective studySevere insulin resistanceNational InstituteGlycaemic controlHDL cholesterolLDL cholesterolTotal cholesterolMetabolic abnormalitiesKidney diseaseProspective studyInsulin resistanceRare disorderSustained improvementPatientsAdipose tissueLipodystrophyHuman lipodystrophyPPARγ geneTherapyDyslipidaemia